PHA-568487, a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR), demonstrates rapid brain penetration and reduces oxidative stress and neuroinflammation.

PHA 568487 enhances anti-oxidant gene expression while reducing oxidative stress and NF-κB p65 phosphorylation. Conversely, Methyllycaconitine (MLA) exhibits opposite effects [2]. Additionally, PHA upregulates anti-oxidant genes and NADPH oxidase expression, correlating with diminished NF-kB p65 phosphorylation within microglia/macrophages [3].

PHA 568487 effectively mitigates neuronal damage and functional impairments in mice and rats suffering from ischemic stroke, with and without concurrent tibia fracture. In C57BL/6J male mice models, PHA 568487 and Methyllycaconitine (MLA) administered intraperitoneally on the first two days post-middle cerebral artery occlusion (pMCAO) demonstrated the most pronounced reduction in cerebral infarction and improvement in behavioral outcomes. Similarly, in adult male Sprague-Dawley rats, a daily intraperitoneal injection of PHA 568487 significantly decreased infarct volumes and enhanced neurological results, marking a notable improvement in recovery from ischemic conditions.